Management ChangeMay 21, 2026, 05:02 PM
Pelthos Therapeutics CFO Knuettel Departs; Grant Thornton New Auditor
AI Summary
Pelthos Therapeutics Inc. formalized the separation terms for its former Chief Financial Officer, Treasurer, and Secretary, Francis Knuettel II, who was terminated effective April 10, 2026. The Separation Agreement, executed on May 15, 2026, includes a severance payment of $430,000 and accelerated vesting of certain stock options and restricted stock units. Concurrently, the company dismissed CBIZ CPAs P.C. as its independent registered public accounting firm and appointed Grant Thornton LLP for the fiscal year ending December 31, 2026, noting no disagreements with the former auditor.
Key Highlights
- CFO Francis Knuettel II's employment was terminated effective April 10, 2026.
- Separation Agreement provides Mr. Knuettel with $430,000 in severance pay.
- Options and RSUs granted to Mr. Knuettel will accelerate vesting for 12 months post-separation.
- Audit Committee dismissed CBIZ CPAs P.C. as independent auditor on May 16, 2026.
- Grant Thornton LLP was engaged as the new independent auditor for fiscal year 2026.
- No disagreements or reportable events were reported with former auditor CBIZ.
Price Impact
More from PTHS